Abstracts tagged "prednisolone"

Abstract Number: 2603 • 2016 ACR/ARHP Annual Meeting
Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone
Ara H. Dikranian¹, Rubaiya Mallay², Mike Marshall³, Megan Francis-Sedlak³ and Robert J. Holt^4,5, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Suncoast Internal Medicine Consultants and Largo Med Center, Largo, FL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Medical Affairs, Horizon Pharma, Inc, Lake Forest, IL, ⁵College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL
Background/Purpose: Patients with RA have previously demonstrated significant differences in morning stiffness (MS), a debilitating symptom of RA, and other disease measures with delayed release…
Abstract Number: 2599 • 2015 ACR/ARHP Annual Meeting
The Effect of Daily Low Dose Prednisone (divided daily versus single daily dose) in the Treatment of African Americans (AA) with Early Rheumatoid Arthritis (RA)
Athan Tiliakos¹, Kirk Easley², Gaobin Bao³, Shuling Liu⁴, S. Louis Bridges Jr.⁵, Leigh F. Callahan⁶, Larry W. Moreland⁷ and Doyt L. Conn¹, ¹Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ²Biostatistics, Emory University, Atlanta, GA, ³Medicine, Emory University, Atlanta, GA, ⁴Biostatistics and Bioinformatics, Emory University School of Medicine, Atlanta, GA, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ⁷Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: To describe the longitudinal changes in the number of swollen and tender joints and HAQ scores in 345 African Americans with early RA and…
Abstract Number: 2656 • 2015 ACR/ARHP Annual Meeting
Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards
Rieke Alten¹, Robert J. Holt², Jeffrey D. Kent³ and Frank Buttgereit⁴, ¹Charité Univ Medicine, Berlin, Germany, ²College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ³Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ⁴Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Patient reported outcomes such as morning stiffness are reported frequently in rheumatoid arthritis (RA) patients. But little has been reported about the presence and…
Abstract Number: 50 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes Associated with Early Corticosteroid Use in a Large Multicenter Canadian RA Cohort
Kathleen Andersen¹, Daming Lin², Susan J. Bartlett^3,4, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰, Diane Tin¹¹, J Carter Thorne¹², VP Bykerk^13,14 and CATCH Investigators, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Institut de Rhumatologie, Montreal, QC, Canada, ⁷Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada
Background/Purpose: Synthetic glucocorticoids (steroids) are commonly used in RA to rapidly inhibit pro-inflammatory cytokines. They are frequently used as "bridge therapy", quickly dampening down the…
Abstract Number: 118 • 2015 ACR/ARHP Annual Meeting
Identifying the Investment Needed to Generate a Durable Prednisone Dose Decrement
Martha Delgado¹, Lorena Wilson², James D. Katz³ and Ann Biehl⁴, ¹the National Institute of Arthritis Musculoskeletal and Skin Diseases, the National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institutes of Health, Bethesda, MD, ³Department of Medicine, Division of Rheumatology, The George Washington University, Washington, DC, ⁴Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD
Background/Purpose: Assessment of the total cost of care requires clinical, epidemiological, patient-centered, and economic data. However, barriers to a value-driven outcome assessment include the resource-intensive…
Abstract Number: 739 • 2015 ACR/ARHP Annual Meeting
Prednisone Increases Both Arterial and Venous Thrombosis in SLE
Katharine Hickman¹, Laurence S Magder² and Michelle Petri³, ¹University College London, London, United Kingdom, ²University of Maryland School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University Hospital, Baltimore, MD
Background/Purpose: An increasing number of studies have investigated factors that are associated with thrombosis in SLE. However, few have examined risk factors specific for venous…
Abstract Number: 1564 • 2015 ACR/ARHP Annual Meeting
Initiation of Disease Modifying Therapies and Subsequent Weight Change in Rheumatoid Arthritis
Joshua Baker¹, Brian Sauer², Kaleb Michaud³, Grant W. Cannon⁴, Said Ibrahim⁵, Liron Caplan⁶, Lisa A. Davis⁶, Amy C. Cannella⁷ and Ted R. Mikuls⁸, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁴Internal Medicine, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ⁷Section of Rheumatology, University of Nebraska Med Ctr, Omaha, NE, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Low body mass index (BMI) predicts adverse outcomes in rheumatoid arthritis (RA), in part due to weight loss among patients with severe disease and…
Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Nazim Reshiti², Toni Kaegi³, Axel Finckh⁴, Hendrik Schulze-Koops⁵, Michael H. Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, St. Gallen, Switzerland, ³Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ⁶School of Medicine, University of Colorado, Denver, CO, ⁷Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…
Abstract Number: 1482 • 2014 ACR/ARHP Annual Meeting
Response of Patient Reported Symptoms of Stiffness and Pain during the Day from Adding Low-Dose Delayed-Release (DR) Prednisone to Stable DMARD Therapy over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA)
Rieke Alten¹, Amy Y. Grahn², Patricia Rice³, Robert Holt⁴ and Frank Buttgereit⁵, ¹Charité University Medicine, Berlin, Germany, ²Horizon Pharma, Inc., Deerfield, IL, ³Premier Research, Naperville, IL, ⁴College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ⁵Charité University Hospital, Berlin, Germany
Background/Purpose: RA patients experience stiffness which impacts their daily lives. Although this patient reported symptom was dropped from the RA classification criteria there is growing…
Abstract Number: 1253 • 2014 ACR/ARHP Annual Meeting
Anakinra – a Promising New Therapy for Idiopathic Recurrent Pericarditis
Sonia Jain¹, Charat Thongprayoon², Raul Espinosa¹, Sharonne Hayes¹, Kyle Klarich¹, Kevin Moder³, Nandan Anavekar¹, Jae Oh¹ and Eric L. Matteson⁴, ¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Idiopathic recurrent pericarditis (IRP) is a debilitating condition that can be recalcitrant to conventional therapy. Some patients develop steroid dependency with the attendant risks…
Abstract Number: 223 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Clinical Vertebral Fractures in Japanese Men and Women with Rheumatoid Arthritis: Results from a Large Prospective Observational Cohort Study
Osamu Ishida¹, Takefumi Furuya², Eisuke Inoue³, Kensuke Ochi², Katsunori Ikari², Atsuo Taniguchi⁴, Hisashi Yamanaka² and Shigeki Momohara⁴, ¹Orthopedics, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at high risk of developing vertebral fractures. Previously, utilizing data from our Institute of Rheumatology Rheumatoid Arthritis (IORRA)…
Abstract Number: 2255 • 2013 ACR/ARHP Annual Meeting
Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year
Frank Buttgereit¹, Jeffery Kent², Robert Holt², Amy Grahn³, Patricia Rice⁴, Rieke Alten⁵ and Yusuf Yazici⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶New York University, New York, NY
Background/Purpose: RA patients typically present with pain and morning stiffness (MS) in addition to joint swelling and tenderness. Nocturnal inflammatory cytokines are assumed to be…
Abstract Number: 2265 • 2013 ACR/ARHP Annual Meeting
Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)
Rieke Alten¹, Robert Holt², Amy Grahn³, Patricia Rice⁴, Jeffery Kent², Frank Buttgereit⁵ and Allan Gibofsky⁶, ¹Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁶Medicine and Public Health, Hospital for Special Surgery, New York, NY
Background/Purpose: A surge in nocturnal inflammatory cytokines causing morning stiffness (MS) is recognized as a therapeutic target in RA. MS has been underappreciated in…
Abstract Number: 2266 • 2013 ACR/ARHP Annual Meeting
Research On Factors Influenced For Bone Metabolic Markers In Rheumatoid Arthritis Patients From Prospective Cohort Study
Masahiro Tada¹, Tatsuya Koike², Tadashi Okano¹, Yuko Sugioka¹, Kenji Mamoto¹, Kentaro Inui³ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) develop osteoporosis more frequently than healthy individuals. Bone resorption and formation are respectively increased and inhibited in patients with…
Abstract Number: 2026 • 2013 ACR/ARHP Annual Meeting
Initial Dose Of Prednisolone For Japanese Patients With Polymyalgia Rheumatica
Akiko Aoki¹, Hiroshi Oka² and Mitsuyuki Nakamura³, ¹General Medicien, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan, ²Rheumatic Disease Center, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan, ³Rheumatology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory condition of elderly persons. Clinical symptoms respond to low-dose glucocorticoids, but treatment is often required for several…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].